Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China

All-oral direct-acting antiviral therapies are becoming the choice for hepatitis C (HCV) treatment. In this study, we aimed to evaluate the efficacy and safety of ritonavir-boosted danoprevir (DNVr) plus sofosbuvir±ribavirin on HCV genotype 1, 2, 3, or 6 in the real world in China. In this observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Shufang, Feng, Kai, Huang, Ping, Zeng, Yingfu, Ke, Liu, Yang, Xiaodong, Liu, Jing, Lin, Chaoshuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213259/
https://www.ncbi.nlm.nih.gov/pubmed/34128871
http://dx.doi.org/10.1097/MD.0000000000026312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213259/
https://www.ncbi.nlm.nih.gov/pubmed/34128871
http://dx.doi.org/10.1097/MD.0000000000026312

Ejemplares similares